Immunome, Inc.
IMNM
$15.67
-$0.82-4.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.59M | 10.94M | 9.04M | 10.13M | 10.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.59M | 10.94M | 9.04M | 10.13M | 10.78M |
| Cost of Revenue | 124.20M | 123.00M | 101.50M | 63.25M | 29.87M |
| Gross Profit | -111.61M | -112.07M | -92.46M | -53.12M | -19.09M |
| SG&A Expenses | 40.70M | 37.64M | 32.96M | 30.55M | 25.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 203.12M | 188.69M | 162.50M | 121.84M | 83.31M |
| Operating Income | -190.53M | -177.75M | -153.46M | -111.71M | -72.53M |
| Income Before Tax | -212.39M | -205.11M | -292.96M | -305.35M | -262.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -212.39 | -205.11 | -292.96 | -305.35 | -262.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -212.39M | -205.11M | -292.96M | -305.35M | -262.59M |
| EBIT | -190.53M | -177.75M | -153.46M | -111.71M | -72.53M |
| EBITDA | -188.42M | -175.73M | -151.89M | -110.44M | -71.56M |
| EPS Basic | -3.08 | -3.19 | -5.17 | -6.06 | -5.64 |
| Normalized Basic EPS | -1.58 | -1.58 | -1.47 | -1.12 | -0.92 |
| EPS Diluted | -3.09 | -3.19 | -5.18 | -6.06 | -5.64 |
| Normalized Diluted EPS | -1.58 | -1.58 | -1.47 | -1.12 | -0.92 |
| Average Basic Shares Outstanding | 289.47M | 262.39M | 234.53M | 214.48M | 166.48M |
| Average Diluted Shares Outstanding | 289.47M | 262.39M | 234.53M | 214.48M | 166.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |